Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
By Ben Glickman
Bristol Myers Squibb's said a trial of its drug Zeposia to treat Crohn's disease didn't meet its goals, potentially squashing a new indication for the treatment.
The pharmaceutical giant said on Thursday the trial failed to reach its primary endpoint of clinical remission for moderate to severe active Crohn's disease at week 12, based on an initial analysis. Bristol Myers Squibb said it would complete a full evaluation of the trial data and share results with the scientific community.
Zeposia is approved by regulators for treatment of multiple sclerosis and ulcerative colitis.
Crohn's is a chronic inflammatory bowel disease which affects the digestive tract.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 28, 2024 16:42 ET (20:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth